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Laboratory and clinical diagnostic classiﬁcation of seropositive individuals, followed by treatment and
supportive therapy, is an established component of Chagas’ disease control in areas where this disease is
endemic. However, most Chagas’ disease patients live in remote areas where neither equipped laboratories
nor skilled human resources are widely available. Employing a rapid diagnostic test (RDT), when using
whole blood samples, is the best option for Chagas’ disease control. A high sensitivity and speciﬁcity for
the Chagas Stat-Pak RDT (Chembio Diagnostic Systems, Inc., Medford, NY) has been reported for assays
using serum and plasma, but its validity for the detection of antibodies to Trypanosoma cruzi infection in
whole blood is unknown. This cross-sectional study measured the sensitivity and speciﬁcity of the Chagas
Stat-Pak with whole blood, using conventional serological assays for comparison. The interobserver
reliability in the interpretation of the Chagas Stat-Pak results and “ease-of-use” criterion needed to
perform the Chagas Stat-Pak and conventional assays were also measured. The Chagas Stat-Pak yielded
a high speciﬁcity (99.0%, 95% conﬁdence interval [CI]  98.4 to 99.4%) but a relatively low sensitivity
(93.4%, 95% CI  87.4 to 97.1%). The interobserver reliability was excellent (kappa [n  1,913]  0.999,
P < 0.0001), and the quantiﬁed ease-of-use criterion suggested that the RDT is simple to perform. Despite
the attributes of the Chagas Stat-Pak, it is not an ideal diagnostic test for the population investigated in
the present study due to its relatively low sensitivity and high cost. The RDT manufacturer is called upon
to improve the test if the international community hopes to make progress in controlling Chagas infections
in areas where this disease is endemic.
Chagas’ disease, or American trypanosomiasis, an endemic
disease from Mexico to southern Argentina, is caused by the
Trypanosoma cruzi parasite. An estimated 13 million people
are infected worldwide; of those, more than 14,000 die each
year (24). Transmission of the disease to mammalian hosts
occurs by infected feces of a blood-sucking triatomine insect
through a break in the skin or through conjunctive or oral
mucosa. Transmission through blood transfusion and preg-
nancy and delivery are also possible and, less frequently, trans-
mission occurs via organ transplantation and laboratory acci-
dent (12). Oral transmission, especially in speciﬁc areas such as
the Amazon Basin, has been reported (1).
Chagas’ disease causes serious illness in humans. Many peo-
ple become infected during childhood or adolescence. Usually,
the early stage of infection is not severe. However, death dur-
ing the early stage may occur, particularly in infants and the
immunosuppressed. For about one-third of the persons who
contract Chagas’ disease, cardiac, digestive, and neurological
sequelae may develop 10 to 20 years after the initial infection
(5). Based upon a synthesis of prior studies, individuals devel-
oping these chronic symptoms may expect a decrease in life
expectancy by an average of 9 years (5, 13–16, 21).
Bolivia reports one of the highest Chagas infection rates in
Latin America, with an area of endemicity covering 80% of its
territory. In the 1980s it was estimated that 1 to 2 million
people, or 22% of the Bolivian population, were infected with
T. cruzi (23). Among recent Chagas’ disease studies in Bolivia,
Albarracin-Veizaga et al. (2) reported a seroprevalence of
anti-Trypanosoma cruzi immunoglobulin G antibodies in
12.5% of individuals aged 10 years or older in a periurban area
of Cochabamba municipality. Breniere et al. (4) reported a
seroprevalence of 43.3% in a rural population within the
Cochabamba Department, with a 21% prevalence of abnormal
electrocardiograms. Me ´decins Sans Frontie `res (MSF), based
upon previous Chagas’ disease treatment programs, estimated
the prevalence of Chagasic infections among young children
and adolescents in the region of Sucre, Bolivia, to be ca. 4.0%
(internal MSF project reports 2004 to 2007 [unpublished
data]).
Laboratory and clinical diagnostic classiﬁcation of seropos-
itive individuals, particularly during childhood and adoles-
cence, is paramount to providing effective treatment and sup-
portive therapy. In Bolivia, under the direction of the Bolivian
National Chagas Programme, the conventional serological as-
says for diagnostic classiﬁcation of T. cruzi infection are the
conventional enzyme-linked immunosorbent assay (ELISA),
the indirect hemagglutination assay (IHA) and as a conﬁrma-
tion assay, the recombinant ELISA. Diagnosis with these con-
ventional assays is routinely conducted in laboratories based in
large urban centers.
However, most Chagas’ disease patients live in periurban
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 and rural areas where neither equipped laboratories nor
skilled human resources are widely available. Speciﬁc con-
straints in remote areas result in delays, losses to patient fol-
low-up, and high healthcare costs. These include complex di-
agnostic protocols requiring at least two patient visits to the
health center or laboratory, lack of or difﬁculty in accessing
health centers, inadequately equipped laboratories (no elec-
tricity, refrigeration, or conventional serological assays), lack
of skilled human resources, and low diagnostic conﬁrmation
processing speed. Moreover, conventional assays when used in
remote areas may lose their published high sensitivity and
speciﬁcity achieved when conducted under reference labora-
tory conditions (3).
The Chagas Stat-Pak (Chembio Diagnostic Systems, Inc.,
Medford, NY) is a rapid immunochromatographic assay for
detection of antibody to T. cruzi. According to the manufac-
turer, this simple (one-step) rapid diagnostic test (RDT) can
be conducted with serum, plasma, or whole blood samples and
is performed in precisely 15 min. Neither refrigeration, nor a
laboratory structure, nor specialized human skills are required
for the performance of this test. In addition, in dry and con-
stant room temperatures specimens can be stored for extended
periods of time for result checking and documentation (10).
The high sensitivity and speciﬁcity of the Chagas Stat-Pak
RDT, when assayed with serum and plasma, is well established
in previous studies (10, 11). In a blinded study (10), the Chagas
Stat-Pak RDT identiﬁed infected and uninfected individuals
with a sensitivity of 98.5% and a speciﬁcity of 94.8%. The study
also independently evaluated serum from four Latin American
countries and found a sensitivity of 100% and a speciﬁcity of
98.6%. A third set of tests comparing sera with plasma and
eluates from ﬁlter paper yielded results identical to those ob-
tained with serum. The performance of the Chagas Stat-Pak
RDT was also compared to a standard ELISA diagnostic assay
in the serodiagnosis of Chagas’ disease in Central America
(11). Of 3,400 blood donor samples, 4.6% were positive in both
assays. Three sera of 2,084 samples from reference laborato-
ries were negative with the RDT but positive with the ELISA
(99.8% agreement). Agreement of 100% between the two tests
was observed with 339 additional sera from patients with car-
diopathies and 175 sera from potential blood donors in emer-
gency surgical cases. The Chagas Stat-Pak showed 99.6% and
99.9% sensitivity and speciﬁcity, respectively, for assays using
5,998 serum samples.
Rationale and objectives. The above-cited studies demon-
strate the validity of Chagas Stat-Pak RDT for the detection of
antibodies to T. cruzi in serum and plasma, but the sensitivity
and speciﬁcity of the RDT when whole blood is tested is
unknown. A highly sensitive and speciﬁc RDT used for diag-
nostic or screening procedures, performed using whole blood
by trained nonlaboratory workers, would circumvent con-
straints associated with conventional serological assays and
bolster Chagas’ disease control efforts. To our knowledge, the
present study is the ﬁrst attempt to validate the performance of
the Chagas Stat-Pak RDT under ﬁeld conditions using whole-
blood samples.
This cross-sectional study describes the demographic char-
acteristics of the study population; evaluates the ability of the
Chagas Stat-Pak RDT, when using whole blood, to correctly
classify individuals as either positive or negative for Chagasic
infection, using conventional serological assays for compari-
son; measures interobserver reliability in the interpretation of
the Chagas Stat-Pak RDT results; and compares the “ease-of-
use” criterion needed to perform the Chagas Stat-Pak RDT
with the ease-of-use criterion of the conventional assays.
MATERIALS AND METHODS
Study location and participants. The present study was conducted in the Valle
Hermoso district located within the city of Sucre, Bolivia. The district has an
approximate population of 46,570 persons at an elevation of 2,790 m and is
located approximately 710 km southwest of the capital, La Paz. The study
sampling frame consisted of individuals aged 9 months to 17.9 years. The district
has an estimated population of 19,120 persons within this target age group.
Two community sensitization teams, consisting of two health workers each,
were sent to the Valle Hermoso district to notify the populace about the study
and recruit eligible individuals. Each team visited all community centers, schools,
and other groups in their designated area and went door-to-door to inform the
community about the study. In addition, all primary health facilities were re-
quested to send potentially eligible individuals for screening.
Children or adolescents were eligible to participate if they met the age criteria,
resided within Valle Hermoso district, and the parent or guardian who accom-
panied them to an MSF-sponsored health clinic signed an informed consent. No
eligible individuals who agreed to participate were excluded from the study. The
enrollment of study participants began on 18 April 2007 and ended on 12 July
2007, a duration of 12 weeks.
Ethics approval and data analysis. This study was approved by the MSF
International Ethics Review Board, the Ethics Committee of San Simo ´n de
Cochabamba University, in agreement with the Bolivian National Chagas Pro-
gramme. The study complied with all relevant federal guidelines and institutional
policies.
Data for each study participant were entered in Microsoft Excel and analyzed
with SPSS 12.0 (SPSS, Inc., Chicago, IL).
Diagnostic test procedures. Once enrolled, 10 l of whole blood was collected
from the study participant using a disposable 10-l Microsafe tube; the amount
needed for the Chagas Stat-Pak RDT. The Chagas Stat-Pak RDT was then
performed and, precisely 15 min later, the result was independently interpreted
by two healthcare workers. Each recorded his or her interpretation in separate
registrars. If there was discordance, a third party was sought to derive consensus
about the test result, and a ﬁnal result was recorded in the patient’s record along
with the original interpretations of the two health workers.
The Chagas Stat-Pak RDT is performed using a speciﬁc antibody-binding
protein that conjugates to dye particles and antigens bound to the test mem-
brane. A whole-blood sample was applied to the sample well and ﬂowed laterally
across the membrane. If the sample contained antibodies to T. cruzi, the complex
bound to the antigens on the membrane, producing a pink and/or purple line
(i.e., the test was considered positive or reactive). If the sample did not contain
antibodies to T. cruzi, the complex remained unbound, and no line appeared (i.e.,
the test was considered negative or nonreactive) (10). Figure 1 presents an image
of reactivity versus nonreactivity demonstrated by the Chagas Stat-Pak RDT.
Next, for each study participant, 3.5 ml of whole blood was obtained by
venipuncture and stored in a dry tube. The specimens were transferred twice
daily, via a temperature-monitored cold box (2 to 8°C), to the MSF Sucre
laboratory for same-day centrifugation and serum extraction in order to perform
the conventional assays. Conventional assays were performed less than 6 h after
sample collection.
Conventional assays, administered serially starting with conventional ELISA
(Chagatest ELISA; Wiener Laboratorios, S.A.I.C., Argentina) and then Chagas
IHA (HAI Chagas Polychaco; Laborato ´rio Lemos, S.R.L., Argentina) and, in the
case of discordance between the two, recombinant ELISA (Chagatest ELISA
recombinante, v.3.0; Wiener Laboratorios, S.A.I.C., Argentina), were used for
diagnostic classiﬁcation and served for comparison for the Chagas Stat-Pak
RDT. In accordance with the Bolivian National Chagas Programme and World
Health Organization technical guidance, in order to be considered Chagas’
disease positive, two out of the three assays had to be positive (i.e., conven-
tional ELISA plus Chagas IHA, Chagas IHA plus recombinant ELISA, or
conventional ELISA plus recombinant ELISA) (23). Conventional ELISA
and recombinant ELISA assay interpretation was performed according to the
manufacturer recommendations. Chagas IHA assay interpretation was con-
sidered positive if agglutination covered 50% of the bottom well of the
titration plate at a titer of 8. The absence of agglutination or agglutination
covering 50% of the bottom well at a titer 8 was considered negative.
VOL. 46, 2008 ASSAY FOR DETECTION OF T. CRUZI INFECTION 2023
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 All individuals found to be Chagas’ disease positive, according to conventional
assays, were offered Benznidazole by the MSF medical team. Benznidazole is the
standard ﬁrst-line treatment for Chagasic infections in Bolivia. Side effects for
benznidazole were reported in 37.3% of treated patients.
Laboratory quality control. Quality control protocols were applied at both
health clinic and laboratory levels. Prior to the initiation of the study, spectro-
photometers and micropipettes were calibrated and thoroughly cleansed by the
level III reference laboratory of the Ministry of Health in Sucre according to
manufacturer-recommended standard procedures. Internal quality control mea-
sures consisted of a weekly analysis of the Chagas Stat-Pak performance with
positive and negative serum controls in the MSF Sucre laboratory according to
the test procedure instructions of all respective package inserts. The procedural
routines of the laboratory and health workers was assessed on a weekly basis by
following a “good practices” checklist. Positive and negative serum controls were
included for each series of conventional assays each time a new microtitration
plate was used in the laboratory. External quality control was carried out by the
level III reference laboratory of the Ministry of Health in Sucre, analyzing a
panel of serum samples (positive and negative) sent from the MSF Sucre labo-
ratory every fourth week.
Measurements of diagnostic test performance. The sensitivity and speciﬁcity
of the Chagas Stat-Pak RDT were calculated. Sensitivity was deﬁned as the
proportion of study participants positive for Chagas’ disease according to the
conventional assays that were correctly identiﬁed as positive by the Chagas
Stat-Pak RDT. Speciﬁcity was deﬁned as the proportion of study participants
without Chagas’ disease according to the conventional assays that were correctly
identiﬁed as negative by the Chagas Stat-Pak RDT.
The interobserver reliability in the interpretation of the Chagas Stat-Pak
results was measured through the calculation of a kappa statistic. This mea-
surement estimated the extent to which the interpretation of the RDT varied
when the test was read independently by two trained, nonlaboratory health-
care workers.
The ease-of-use criterion to perform the Chagas Stat-Pak RDT and the con-
ventional assays were quantiﬁed and compared. At the completion of the study,
both the trained, nonlaboratory health workers who conducted RDT tests and
the laboratory workers who conducted the conventional assays completed a
questionnaire which, in addition to itemizing and scoring general characteristics
of the tests, assessed their perceptions about ease of use in performing the
respective tests. Questionnaire items included documentation of the number of
doubtful and invalid tests and assessment of ease of performance, ease of inter-
pretation, quality of the instruction sheet, ease of opening the package, and ease
of identifying reagents. Each questionnaire item was given an individual score
(range, 1 to 5), a higher score indicating a more favorable response. A total of 51
points was possible.
The questionnaire is a modiﬁcation of a questionnaire designed by Epicentre
(Paris, France) to evaluate an RDT for the diagnosis of uncomplicated Plasmo-
dium falciparum malaria (7). An MSF laboratory technician and coauthor (L.F.)
established content validity of the questionnaire by reviewing the document for
appropriateness and representativeness of the contents.
FIG. 1. Reactivity versus nonreactivity of the Chagas Stat-Pak RDT. From left to right, the ﬁrst and third tests are nonreactive, while the second
is reactive. All three tests produce a control line (top), while a pink/purple line on the second test (bottom) appeared after the T. cruzi antibody
complex bound to the antigens on the membrane.
2024 RODDY ET AL. J. CLIN.M ICROBIOL.
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 RESULTS
Demographics. A total of 1,913 study participants were en-
rolled. Table 1 presents the characteristics of the study popu-
lation. The mean age of participants was 9.3 years (standard
deviation, 4.4) and the median age, 9.0 years (interquartile
range, 6 to 13). Only 331 (17%) of the participants were under
5 years of age compared to 1,582 (83%) participants aged 5 to
17.9 years. Males were slightly under-represented (49%) com-
pared to females (51%) (male/female ratio of 0.95).
Sensitivity and speciﬁcity. In the present study, the Chagas
Stat-Pak RDT correctly detected 113 of the 121 positive results
identiﬁed by the conventional assays, yielding 93.4% sensitivity
(95% conﬁdence interval  87.4 to 97.1%). Likewise, of the
1,792 negative results according to conventional assays, 1,774
were correctly categorized by the RDT, yielding 99.0% speci-
ﬁcity (95% conﬁdence interval  98.4 to 99.4%). Percentages
were calculated using the results presented in Table 2.
Interobserver reliability. A total of four trained, nonlabora-
tory health workers, working in pairs, interpreted the 1,913
Chagas Stat-Pak test results. These individuals concurred on
1,911 of the test results, yielding 99.9% overall agreement (n 
1,913, kappa  0.999, P  0.0001).
Ease-of-use criterion. A total of six individuals conducted
the diagnostic tests and completed ease-of-use criterion for
each of the tests they performed. Two individuals were labo-
ratory workers who performed the three conventional assays,
and four were trained, nonlaboratory health workers who per-
formed the Chagas Stat-Pak RDT only.
Each questionnaire item was scored according to the scheme
outlined in the Materials and Methods section of the present
study. Of a total of 51 possible points, the RDT scored the
highest with 39.25 points (77%), followed by the Chagas IHA
assay with 34 points (67%). The conventional ELISA and re-
combinant ELISA each scored 30 points (59%).
Doubtful tests were reported for 1.0% of the RDTs per-
formed but 1.0% for the three conventional assays. The ease
of performance was reported to be “very simple” for the RDT
but “difﬁcult” for each of the conventional tests. Likewise, the
interpretation of the RDT was reported to be “very simple”
compared to “simple” for the conventional assays. The quality
of the RDT instruction sheet was reported as “above average”
but inferior to the “excellent” quality of the instruction sheets
for the conventional assays. Trained, nonlaboratory health
workers found opening the RDT package cumbersome and
gave this survey item an “average” score only. The RDT test
did not require identiﬁcation of reagents, while laboratory
workers reported the labeling for the identiﬁcation of conven-
tional assay reagents to be excellent.
DISCUSSION
Laboratory and clinical diagnostic classiﬁcation of seropos-
itive individuals, followed by treatment and supportive therapy,
is an established component of Chagas’ disease control in areas
of endemicity. The use of a valid RDT, when whole-blood
samples are used, performed by trained nonlaboratory health-
care workers is the best option for supporting this disease
control component. Effective laboratory-based solutions ap-
plied to rural or periurban areas of endemicity are not widely
available or likely to be anytime in the near future (20).
Overall, the Chagas Stat-Pak RDT is advantageous to the
conventional assays. The RDT takes fewer steps to perform
and is easier to interpret. The RDT can be stored up to 30°C,
but the three conventional assays require refrigeration from 2
to 8°C. RDT results are available precisely 15 min after blood
application while the Chagas IHA, and the two ELISAs re-
quire 3 and 4 h, respectively, to complete. The RDT does not
require additional materials such as a spectrophotometer, mi-
cropipettes, an incubator, a centrifuge, or paraﬁlm that are
necessary to perform the conventional assays. Further, the
RDT has the advantage of dispensing the blood specimen
directly onto the test device, whereas the conventional assays
require a buffer solution to dispense in a test tube.
The conventional assays retain some advantages over the
RDT. The stability of the result is less than 30 min for the RDT
and the ELISAs, while the constancy of Chagas IHA results is
more than 24 h. In Bolivia, the RDT costs between 1 and 2
U.S. dollars (USD) per test. This is more expensive than the
conventional assays, which cost less than 1 USD per test. An
RDT price of 1 USD remains “out of reach” for many impov-
erished people affected by the disease.
A 99% Chagas Stat-Pak RDT speciﬁcity suggests that, had
the RDT been used as a diagnostic assay in the absence of
conventional testing, 1% of screened individuals would have
been treated unnecessarily. The standard ﬁrst-line treatment,
benznidazole, is well tolerated among children and adolescents
but can have serious side effects that include allergic dermop-
athy, peripheral neuropathy, and granulcytopenia (6).
With respect to sensitivity, the Chagas Stat-Pak RDT, when
whole blood is used as the sample medium, compares less
favorably with the whole-blood RDT diagnosis of other para-
sitological vector-borne diseases. The rK39 RDT (DiaMed-IT-
TABLE 1. Characteristics of the study population screened for
Chagas’ disease using the Chagas Stat-Pak RDT and
conventional serological assays in Sucre, Bolivia,
from April to June 2007
Demographic
category
No. of subjects
(n  1,913) % Total
Age
9 mo to 4.9 yr 331 17
5 yr to 17.9 yr 1,582 83
Gender
Male 930 49
Female 983 51
TABLE 2. Two-by-two table of Chagas’ disease classiﬁcation as
deﬁned by using the Chagas Stat-Pak and conventional
serological assays in Sucre, Bolivia, from
April to June 2007
Stat-Pak results
No. of results (n  1,913) obtained by
conventional serology:
Positive Negative Total
Positive 113 18 131
Negative 8 1,774 1,782
Total 121 1,792 1,913
VOL. 46, 2008 ASSAY FOR DETECTION OF T. CRUZI INFECTION 2025
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 Leish) had a reported 100% sensitivity for the diagnosis of
visceral leishmaniasis (17), and the Paracheck-Pf RDT (Orchid
Biomedical Systems, Goa, India) had a reported 99% sensitiv-
ity for the diagnosis of uncomplicated P. falciparum malaria
(18).
In the present study, the Chagas Stat-Pak RDT, using whole
blood, failed to identify eight positive individuals identiﬁed
through conventional assays. The 93.4% sensitivity of the RDT
found in the present study fell short of the Chagasic infection
technical guidance provided by the World Health Organiza-
tion, which states that an ideal test should be easy to perform
in a single step, be fast and inexpensive, require no special
equipment or refrigeration of reagents, and have a sensitivity
and speciﬁcity of 100% (22). The false-negative rate of 6.6%
found in the present study suggests that a substantial number
of individuals remain undiagnosed, resulting in missed treat-
ment opportunities and increased likelihood of chronic-stage
disease sequelae.
In the Valle Hermoso district in Sucre, Bolivia, the Chagas
Stat-Pak was not an ideal screening or diagnostic test. The
sensitivity of the RDT, when conducted under ﬁeld conditions
and using whole-blood samples, was lower than the sensitivity
reported in Chagas Stat-Pak validation studies that used serum
and plasma samples (10, 11). It was noted that four of eight
false-negative RDTs turned positive when the RDT was read
at 20 min rather than the manufacturer-recommended 15 min.
If interpreted at 20 min, the Chagas Stat-Pak RDT test would
have had an improved sensitivity of 96.7%. This observation
does not qualify as “ofﬁcial” test results because the package
insert recommendation that interpretation should occur pre-
cisely 15 min after sample application was not adhered to.
Future validation studies should include interpretation read-
ings at 5-min intervals from 15 to 30 min to ensure that ade-
quate time is allotted for test reactivity.
Cross-reactivity may occur between the sera of patients in-
fected with T. cruzi and the sera of patients infected with
Leishmania spp. when conventional assays are used for the
diagnosis of Chagasic infections (8, 19). This phenomenon may
have accounted for some or all of the eight false-negative
individuals. Persons with negative RDT tests may be true neg-
atives for Chagas’ disease but may have another disease in
which the antibodies cross-reacted with Chagas’ disease anti-
gens in the conventional assays. Had cross-reactivity been as-
sessed, an increased sensitivity for the Chagas Stat-Pak RDT
may have been demonstrated.
Considering the RDTs reported high speciﬁcity (99%), its
high ease-of-use criterion score compared to conventional as-
says, and its excellent interobserver reliability (99.9% overall
agreement) with a kappa statistic suggesting this excellence is
beyond chance alone (9), the results are encouraging. How-
ever, in light of the importance of using whole blood under
ﬁeld conditions, the relatively low sensitivity in comparison to
the sensitivity of the RDT when serum or plasma is used
hinders the ability of this test to give dependable results under
the conditions outlined here. To date, due to a lack of other
options, MSF continues to use whole blood with the Chagas
Stat-Pak RDT when screening a population where the disease
is endemic, with ﬁnal diagnostic classiﬁcation being dependent
upon conventional serological assays.
Conclusion and recommendations. Although the present
study cites numerous advantages that the Chagas Stat-Pak
RDT holds over the conventional assays, future progress for
the control of Chagasic infections in areas of endemicity in
Latin America necessitates research and development initia-
tives to improve the RDT. In remote areas, the use of whole
blood as a sample medium is crucial since it simpliﬁes the test
procedures performed by trained, but nonlaboratory health-
care workers. Thus, the sensitivity and speciﬁcity of an RDT
that uses whole blood should approach the sensitivity and
speciﬁcity of conventional assays that are conducted under
reference laboratory conditions and use plasma or serum. If
possible, the RDT cost should be set as low as possible to
increase accessibility for impoverished people in high-preva-
lence regions.
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